Health & Medicine

Opinion: CMS shouldn't be paying for higher-than-necessary doses of cancer drugs

22 sec read16 views0 listens

The article discusses high cancer drug prices in the U.S., a long-standing issue that exacerbates "financial toxicity" for patients; Congress passed a law in 2022 allowing CMS to negotiate maximum prices for certain brand-name drugs, aiming to mitigate this problem by reducing costs and patient financial burdens.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity11 hours ago28 sec read

AI risk is not just a technology problem: New research shows why leadership matters more than controls

New research from IANS and Artico Search reveals that effective management of AI risks in enterprises depends more on organizational readiness, including leadership understanding and governance structures, rather than just technical security controls...

Ali Nemati

Cybersecurity11 hours ago23 sec read

Rewilding leadership: Can nature provide the blueprint for thriving in an age of disruption?

Leadership strategist Thom Dennis proposes a new approach to management inspired by natural systems, arguing that traditional command-and-control models are inadequate for today's complex business environment. This perspective is crucial as it encour...

Ali Nemati

Cybersecurity16 hours ago22 sec read

When Malware Does Math: The Arms Race Between Sandboxes and Self-Aware Threats

Modern malware is increasingly capable of detecting sandbox environments and remaining inactive to evade detection, using techniques like trigonometry to analyze mouse movements and timing checks. This development challenges traditional security prac...

Ali Nemati